Phase 3 trials of new antiretrovirals are not representative of the global HIV epidemic
Introduction: People living with HIV (PLWH) are mainly African or Asian, the majority female. In contrast, pharmaceutical companies typically conduct phase 3 regulatory randomised controlled trials (RCTs) in high-income countries (HICs), where PLWH are mainly white males. Regulatory authorities can...
Saved in:
Main Authors: | Toby Pepperrell (Author), Andrew Hill (Author), Michelle Moorhouse (Author), Polly Clayden (Author), Kaitlyn McCann (Author), Simiso Sokhela (Author), Celicia Serenata (Author), Willem Daniel Francois Venter (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2020-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety of Antiretrovirals in Pregnancy
by: Polly Clayden
Published: (2009) -
Changes to the ART guidelines - an overview
by: Celicia Serenata
Published: (2010) -
What is the role of CD4 count in a large public health antiretroviral programme?
by: Michelle Moorhouse, et al.
Published: (2016) -
Ten years of ART in South Africa - how far we have come
by: Celicia M Serenata
Published: (2014) -
A review of the safety of favipiravir - a potential treatment in the COVID-19 pandemic?
by: Victoria Pilkington, et al.
Published: (2020)